Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 9Head & Neck 6Breast 3Thoracic 1Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 1

Interventions

Fulvestrant 82Paclitaxel 78Letrozole 76pembrolizumab 71Trastuzumab 63Specimen Handling 63Carboplatin 58Magnetic Resonance Spectroscopy 50ribociclib 49Capecitabine 49Anastrozole 47pertuzumab 46palbociclib 43Cyclophosphamide 41exemestane 40abemaciclib 40Tamoxifen 38Biopsy 36Docetaxel 30trastuzumab deruxtecan 29Taxes 28Radiotherapy 27130-nm albumin-bound paclitaxel 26Gemcitabine 25Blood Specimen Collection 25Surveys and Questionnaires 23olaparib 22Standard of Care 22sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
camrelizumab × Breast × 90 days × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Harbin Medical University

Phase 2 Active not recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡